An international study led by Monash University has, for the first time, harnessed cutting-edge technology to reveal new and unprecedented information of how a special class of drugs, known as “allosteric modulators” work at the M4 muscarinic receptor, a major target for notoriously difficult-to-treat psychiatric disorders associated with cognitive deficits, such as schizophrenia.
Click here for original story, Study unlocks key information on major drug target for psychiatric and cognitive disorders, including schizophrenia
Source: Phys.org